PsychoGenics

Executive Summary

PsychoGenics is a preclinical contract research organization (CRO) specializing in central nervous system (CNS) drug discovery. Founded in 1995 and based in Paramus, New Jersey, the company leverages AI-driven phenotypic screening and behavioral testing to de-risk neurological and psychiatric drug development. Its validated disease models and integrated preclinical services aim to reduce the high clinical attrition rates that plague CNS programs. As a private, pre-clinical entity, PsychoGenics serves pharmaceutical and biotech clients by providing reliable efficacy data and translational biomarkers, positioning itself as a critical partner in advancing therapies for conditions such as Alzheimer's, Parkinson's, depression, and schizophrenia. The company's core competitive advantage lies in its combination of traditional behavioral neuroscience expertise with machine learning analytics, enabling more accurate prediction of drug candidate performance before human trials. With no disclosed funding rounds or valuation, PsychoGenics operates on a fee-for-service model, generating revenue through client collaborations. The CNS CRO market is growing, driven by increasing R&D spend in neuroscience and demand for specialized preclinical capabilities. PsychoGenics is well-positioned to capitalize on this trend, though its private nature limits visibility into financials and partnership depth. Key risks include reliance on a few major clients and competitive pressure from larger CROs expanding their CNS offerings.

Upcoming Catalysts (preview)

• Q3 2026Major pharmaceutical partnership announcement75% success
• Q4 2026Publication of validation data for new AI-driven screening platform60% success
• 2027Expansion into neurodegenerative disease models (e.g., ALS, Huntington's)50% success